Clinical Trials
10
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)β’ Click on a phase to view related trials
Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes
- Conditions
- Type 2 Diabetes MellitusOverweight and Obesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2019-05-24
- Lead Sponsor
- Zafgen, Inc.
- Target Recruit Count
- 188
- Registration Number
- NCT03254368
- Locations
- π¦πΊ
Coffs Harbour GP SuperClinic, Coffs Harbour, New South Wales, Australia
π¦πΊNorthside Health, Coffs Harbour, New South Wales, Australia
π¦πΊThe Aim Centre, Merewether, New South Wales, Australia
An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus
- Conditions
- ObesityType 2 Diabetes
- Interventions
- Drug: ZGN-440 for Injectable SuspensionDrug: ZGN-440 Placebo for Injectable Suspension
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2016-01-06
- Lead Sponsor
- Zafgen, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT02324491
- Locations
- π¦πΊ
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
π¦πΊPendlebury Research, Cardiff, New South Wales, Australia
π¦πΊAustralian Clinical Research Network, Maroubra, New South Wales, Australia
Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome
- Conditions
- Prader-Willi SyndromeObesity
- Interventions
- Drug: ZGN-440 Placebo for Injectable SuspensionDrug: ZGN-440 for Injectable Suspension
- First Posted Date
- 2014-07-01
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Zafgen, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT02179151
- Locations
- πΊπΈ
University of California, Davis, Sacramento, California, United States
πΊπΈUCSD: Rady Children's Hospital, San Diego, California, United States
πΊπΈChildren's Hospital of Colorado, Aurora, Colorado, United States
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury
- Conditions
- ObesityCraniopharyngiomaOver-weightHypothalamic Injury
- Interventions
- Drug: ZGN-440 for injectable suspensionDrug: ZGN-440 sterile diluent
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2016-07-18
- Lead Sponsor
- Zafgen, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02063295
- Locations
- πΊπΈ
Children's Hospitals and Clinics of Minnesota, St. Paul, Minnesota, United States
πΊπΈVanderbilt University Medical Center, Nashville, Tennessee, United States
π¦πΊThe Boden Institute, Sydney, New South Wales, Australia
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome
- Conditions
- ObesityOver-weightPrader-Willi Syndrome
- Interventions
- Drug: 1.8 mg ZGN-440 for injectable suspensionDrug: 1.2 mg ZGN-440 for injectable suspensionDrug: ZGN-440 sterile diluent
- First Posted Date
- 2013-03-27
- Last Posted Date
- 2016-07-18
- Lead Sponsor
- Zafgen, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT01818921
- Locations
- πΊπΈ
University of Florida, Gainesville, Florida, United States
- Prev
- 1
- 2
- Next